A differential impact on OM is perhaps not unexpected given that vaccination with PHiD-CV induces high levels of NTHi-specific (anti-protein D) antibodies, and consistent trends toward vaccine efficacy against NTHi were observed in randomized controlled trials of NTHi protein D conjugated PCVs, with estimates for PHiD-CV ranging between 15% and 22%.17 The gene discussed is DHRS2; the disease is ocular melanoma.